Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forced OTC switch issue returns to FDA

Executive Summary

A new citizen's petition asks FDA to switch two antihistamines, Sanofi-Aventis' Allegra and Pfizer's Zyrtec, to OTC status. The petition, filed March 12 by attorney Joel Stocker of Greenberg Traurig, makes the case that the "positive OTC experience" of Schering-Plough's Claritin "has made the case to switch [Allegra and Zyrtec] even more compelling." Schering initially fought a Wellpoint petition to force an OTC switch of Claritin (along with Allegra and Zyrtec), but later filed a sNDA to switch Claritin (1"The Pink Sheet" Dec. 2, 2002, p. 7). FDA previously declined to act on the petitions for Allegra and Zyrtec...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel